Endomag is a global technology company that believes everyone deserves a better standard of cancer care. Many of the world’s leading physicians and hospitals use the company’s technologies to help women with breast cancer avoid surgery when it isn’t needed - and experience better outcomes when it is.

Originally founded in 2007 by professors at University College London (UCL) and the University of Houston, Endomag harnesses the power of magnetics to enable a better standard of cancer care.

At the heart of the company’s product platform is the Sentimag® localisation system. The Sentimag® system features a probe which works like a metal detector. When placed near the skin’s surface it will detect cancerous tissue that has been marked by either Endomag’s magnetic seed (the Magseed® marker) or liquid tracer (the Magtrace® lymphatic tracer).

The Sentimag® system with Magseed® and Magtrace® offers a wire-free, radiation-free alternative to the traditional solutions and is the only platform currently available that allows physicians to perform both tissue localisation and sentinel node biopsy procedures.

Thousands of physicians from over 40 countries around the world are now using the Sentimag® platform to deliver better treatment to their patients.

Endomag is a global company headquartered in Cambridge, UK, with an office in Austin, Texas. To date, the company has helped over 180,000 women around the world access more precise and less invasive breast cancer care.